+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.

Age: 18Years +All GendersPhase 3
1151 locations
E

Actively Recruiting

This trial studies patients with rare genitourinary tumors that have spread from their original site to other parts of the body. It evaluates the combination of cabozantinib with two immunotherapy drugs, nivolumab and ipilimumab, to see how well this approach works. The study focuses on patients who have few or no treatment options, aiming to assess response rates and survival outcomes. Participants receive cabozantinib orally daily on specific days during treatment cycles, alongside nivolumab and ipilimumab given intravenously at the start of initial cycles. After four cycles, nivolumab is continued alone every 28 days. Treatment continues for up to two years unless the disease progresses or side effects are unacceptable. Imaging tests like CT, MRI, bone scans, and PETCT scans are performed throughout the study to monitor disease and treatment effects. During the trial, patients undergo various assessments including echocardiography, blood and urine tests, and scans to track tumor response and safety. After completing treatment, participants are followed every two months for up to five years to observe long-term outcomes. The main focus is on objective tumor response, with additional monitoring of survival and side effects over time.

Age: 18Years +All GendersPhase 2
582 locations
P

Actively Recruiting

Researchers are evaluating the effect of chemotherapy drugs capecitabine and temozolomide after surgery in patients with high-risk well-differentiated pancreatic neuroendocrine tumors. This phase II trial compares treatment with these drugs to observation only, aiming to see if chemotherapy can prevent or delay cancer recurrence and improve survival. The study also assesses the safety and tolerability of this chemotherapy combination and collects specimens for future research. Participants are randomly assigned to one of two groups. In the first group, patients take capecitabine twice daily on days 1 to 14 and temozolomide once daily on days 10 to 14, repeating this 28-day cycle for up to 4 cycles if there is no disease progression or unacceptable side effects. The second group undergoes surveillance without active treatment. After treatment or observation, all patients are followed every 6 months for 3 years, then annually until 5 years from randomization. During the study, participants will have regular medical exams and scans to monitor for cancer recurrence or progression. Researchers will assess recurrence-free survival as the primary outcome over up to 5 years, with overall survival and side effects also tracked. Safety evaluations are done up to 30 days after treatment completion. This long-term follow-up helps understand how well patients do after surgery with or without chemotherapy.

Age: 18Years +All GendersPhase 2
448 locations